Last reviewed · How we verify
GDC 695
GDC 695 is a small molecule targeting the PI3K delta (p110δ) subunit.
GDC 695 is a small molecule targeting the PI3K delta (p110δ) subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | GDC 695 |
|---|---|
| Sponsor | Balmoral Medical company |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta (p110δ) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GDC 695 works by inhibiting the PI3K delta subunit, which plays a key role in the activation of immune cells. This inhibition can lead to a reduction in the activity of these cells, potentially reducing inflammation and autoimmune responses.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GDC 695 CI brief — competitive landscape report
- GDC 695 updates RSS · CI watch RSS
- Balmoral Medical company portfolio CI